TWA
ITOS

TCI Wealth Advisors’s iTeos Therapeutics ITOS Stock Holding History

TCI Wealth Advisors’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-226
Closed -$3.08K – 1197
2023
Q1 		$3.08K Hold
226
– – ﹤0.01% 1843
2022
Q4 		$4.41K Hold
226
– – ﹤0.01% 1611
2022
Q3 		$4K Hold
226
– – ﹤0.01% 1618
2022
Q2 		$5K Buy
+226
New +$5.36K ﹤0.01% 1496

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TCI Wealth Advisors's ITOS Position: Q2 2023 in Review

TCI Wealth Advisors sold out of iTeos Therapeutics (ITOS) in Q2 2023, closing a stake of 226 shares — an estimated $3.08K sold.

TCI Wealth Advisors first reported a position in ITOS in Q2 2022 and held it in 4 quarters. The position peaked at $5K in Q2 2022. 146 funds tracked by Wall St. Rank hold ITOS as of Q2 2023.

  • TCI Wealth Advisors reported no remaining iTeos Therapeutics position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 226 iTeos Therapeutics shares in Q2 2023, an estimated $3.08K.
  • TCI Wealth Advisors first reported a position in iTeos Therapeutics in Q2 2022 and held it in 4 quarters.
  • TCI Wealth Advisors's iTeos Therapeutics position peaked at $5K in Q2 2022.
  • 146 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.